Tofacitinib is an oral Janus kinase (JAK) inhibitor that selectively targets JAK1 and JAK3, thereby modulating cytokine-mediated signalling and reducing inflammation in psoriatic arthritis (PsA) (1,2). Through inhibition of these intracellular pathways, tofacitinib decreases synovial inflammation, pain, and swelling, and improves joint function and
697 Reached1 Comments
Rubella Syndrome in Neonate
1401 Reached12 Comments9 Likes
Black Lesion in Old Female
1974 Reached5 Comments11 Likes
Chronic Hyperplastic Candidiasis Of The Oral Mucosa
858 Reached9 Comments11 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes